 |
| |
| |
NICE gives green light to new clot-busting drug
|
|
| |
NICE has recommended the use of ticagrelor (Brilique), in combination with low-dose aspirin for up to 12 months, for patients with acute coronary syndromes (ACS). Ticagrelor is an anti-platelet drug which works by reducing or preventing the formation of blood clots.
|
|
|
| |
| |
Greater management of hyperglycaemia in patients with acute coronary syndromes needed
|
|
| |
Patients with acute coronary syndromes (ACS) should have their blood glucose levels actively controlled if it is raised on admission to hospital, says NICE. Currently, hyperglycaemia is not being considered as a risk factor for ACS and frequently remains untreated.
|
|
|
| |
|
|
|
 |
| |
| |
Government plans to tackle obesity unveiled
NICE is to support local authorities in developing ways to tackle the rising tide of obesity in England, as the government plans to slash five billion calories off the nation's daily diet. On average adults are exceeding their daily calorie intake by 10 per cent, and people need to be more honest about what they eat and drink, according to the government's obesity strategy.
|
|
| |
|
|
| |
|
|
|
|
|
| |
| |
Share your story on using NICE guidance for prestigious award
NICE is calling on organisations which have tried creative new ways to put NICE guidance into practice to enter the 2012 NICE Shared Learning Awards. Any organisation that uses NICE guidance is encouraged to apply. This includes NHS services, local authorities, charities, community groups or even private workplaces.
|
|
| |
|
|
| |
|
|
|
|
 |
| |
| |
New tools for hip fracture and rheumatoid arthritis
NICE has produced an online training module to help nurses with the management of hip fracture. The module covers the clinical and wider implications of having a hip fracture, and explains the importance of a co-ordinated multidisciplinary hip fracture programme and rehabilitation care.
An
| |
| |
|
|
| |
|
|
|
|
 |
| |
| |
Have your say on draft guidance which recommends against the use of ipilmumab for the treatment of advanced malignant melanoma in people who have received prior chemotherapy. On the basis of evidence given so far, ipilimumab is not cost effective for use on the NHS.
|
|
|
| |
| |
Comment on draft recommendations on identifying and managing tuberculosis among hard-to-reach groups such as substance misusers and some migrant populations. These groups often have difficulty recognising symptoms, accessing health services and taking medication.
|
|
|
| |
|
|
|
|
|
